恩华药业股票讨论区

Investors expect limited growth for Jiangsu Nhwa Pharmaceutical, reflected in a low P/E ratio. The inferior earnings outlook compared to the market justifies this lowered P/E. Dismal earnings could further hinder the share price increase.

Given Jiangsu Nhwa Pharmaceutical's significant investment and lucrative return rate, earnings are projected to rise substantially. Despite uncertainty in analysts' projections, performance is deemed satisfactory, fueling expectations for accelerated earnings growth due to low payout ratios.